Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo attack on head and neck cancer shows promise in early trial

NCT ID NCT06211335

First seen Mar 19, 2026 · Last updated May 20, 2026 · Updated 10 times

Summary

This early-phase study tests whether combining a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and precise radiation (SBRT) is safe and effective for people with head and neck cancer that has come back or spread. About 24 adults with limited metastatic disease will receive the combination. The goal is to find a better way to control the cancer when standard treatments have stopped working.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Colorado Denver | Anschutz Medical Campus

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.